Journals / Türk Kardiyoloji Derneği Arşivi / 2021 / Cilt: 49 - Sayı: 1

Takotsubo syndrome after treatment with non-cardiotoxic chemotherapy agents

Kardiyotoksik olmayan kemoterapötik sonrası Takotsubo sendromu

Pages
72–75
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case report describes a case of TTS developing within hours of gemcitabine and vinorelbine chemotherapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Summary– Takotsubo syndrome (TTS), acute stress-induced cardiomyopathy, is known to have a dramatic clinical presentation mimicking acute myocardial infarction.
📊
Key Findings & Data:Recently developed chemotherapeutic drugs have resulted in improvements in morbidity and mortality in many forms of cancer.
💡
Conclusion & Impact:This case report describes a case of TTS developing within hours of gemcitabine and vinorelbine chemotherapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Summary– Takotsubo syndrome (TTS), acute stress-induced cardiomyopathy, is known to have a dramatic clinical presentation mimicking acute myocardial infarction. Recently developed chemotherapeutic drugs have resulted in improvements in morbidity and mortality in many forms of cancer. However, some chemotherapeutic drugs are cardiotoxic and may cause heart failure. Gemcitabine and vinorelbine are commonly used drugs for various solid organ neoplasms. While neither of these chemotherapeutic drugs has been directly associated with cardiotoxicity, there are a few case reports in the literature related to gemcitabine treatment-induced cardiomyopathy. This case report describes a case of TTS developing within hours of gemcitabine and vinorelbine chemotherapy.

Özet

Özet– Akut stres ile tetiklenen Takotsubo sendromu (TTS), akut miyokart enfarktsü ile sıklıkla karıştırılan, dramatik klinik seyri olan bir kardiyomiyopatidir. Son yıllarda kanser tedavisi alanındaki gelişmeler ile kansere bağlı morbidite ve mortalitede olumlu gelişmeler yaşanmıştır. Ancak, bazı kemoterapötik ilaçlara bağlı kardiyotoksisite gelişmekte ve kalp yetersizliği ve ölümcül ritim bozukluğuna yol açabilmektedir. Gemsitabin ve vinorelbin solid organ kanserlerinde tercih edilen kempoterapi ilaçlarıdır. Her iki kemoterapi ajanın doğrudan kardiyotoksisitesi ile ilgili literatürde veri bulunmamaktadır. Gemsitabine bağlı kardiyomiyopati gelişebileceğine dair sadece birkaç olgu sunumu mevcuttur. Burada, gemsitabin ve vinorebin sonrası ani gelişen TTS sendromu olgusu bildirilmiştir.

🔖

Cite This Article

Şimşek, E., Kültürsay, H., Kemal, H. S., Gürses, E., Özbay, B. (2022). Takotsubo syndrome after treatment with non-cardiotoxic chemotherapy agents. Türk Kardiyoloji Derneği Arşivi, Cilt: 49 - Sayı: 1, 72–75. https://ajindex.com/articles/631840

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Rouprêt M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. Eur Urol 2018;73:111−22
  2. Khan MF, Gottesman S, Boyella R, Juneman E. Gemcitabine-induced cardiomyopathy: a case report and review of the literature. J Med Case Rep 2014;8:220
  3. Dasanu CA. Gemcitabine: vascular toxicity and prothrombotic potential. Expert Opin Drug Saf 2008;7:703–16
  4. Nef HM, Möllmann H, Akashi YJ, Hamm CW. Mechanisms of stress (Takotsubo) cardiomyopathy. Nat Rev Cardiol 2010;7:187−93
  5. Lapeyre-Mestre et al. Vinorelbine-related Cardiac Events: A Meta-Analysis of Randomized Clinical Trials. Fundam Clin Pharmacol 2004;18:97−105